United BioPharma (UBP) specializes in the development and commercialization of proprietary monoclonal antibodies (mAbs) aimed at addressing significant healthcare challenges. The company has established advanced antibody platform technologies that facilitate the generation of stable, high-productivity, and serum-free clones for large-scale mAb production. UBP's integrated technology platform encompasses competitive cell and protein process development, characterization, and analytical methods, which collectively enhance the efficiency of their production processes. This allows UBP to achieve high titer and robust cell culture, resulting in optimized yields and high-quality purification of their antibodies.

In addition to their innovative mAb development capabilities, UBP operates a state-of-the-art cGMP manufacturing facility, recognized as the largest in Taiwan. This facility is equipped with sophisticated instruments that support commercial-scale manufacturing, ensuring that UBP can meet the demands of the biopharmaceutical market. The combination of their cutting-edge research and development infrastructure with their manufacturing capabilities positions UBP as a leader in the biotechnology sector, dedicated to delivering impactful therapeutic solutions to patients.

Taiwan

United BioPharma (UBP) was established in September 2013 as a spinoff company from UBI which was founded in 1985 in the USA.

UBP focuses on developing, manufacturing, and marketing integrated therapeutic mAb products and related technologies. In addition, UBP also provides fully integrated and high-quality CDMO services. We commit to meeting our client's needs. Among +250 employees, 50% are in R&D and 65% have a master’s degree or higher.

Global facilities of UBP include clinical development, R&D, manufacturing centers in Taiwan and China, as well as business centers in the USA and Taiwan.

United Biopharma

Company Details